By Justin Petrone

Spanish biotech firm Progenika Biopharma recently announced two separate deals to make its array technology and expertise available to partners.

In the first deal, announced last week, Progenika together with Amsterdam Molecular Therapeutics aims to develop and market an array-based test to identify patients who have lipoprotein lipase deficiency and may be candidates for AMT's Glybera gene therapy.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.